What is the recommended regimen for using targeted‑release budesonide in adult patients with biopsy‑proven IgA nephropathy who have an estimated glomerular filtration rate ≥35 mL/min/1.73 m² and persistent proteinuria ≥0.5 g/24 h despite optimized renin‑angiotensin system blockade?

Targeted-Release Budesonide for IgA Nephropathy

For adult patients with biopsy-proven IgA nephropathy meeting your criteria (eGFR ≥35 mL/min/1.73 m², persistent proteinuria ≥0.5 g/24h despite optimized RAS blockade), administer targeted-release budesonide (Nefecon) 16 mg once daily in the morning for 9 months, followed by discontinuation and continued supportive care. 1

Dosing Regimen

• Dose: 16 mg once daily
• Timing: Morning administration, with or without food
• Duration: 9 months of active treatment
• Administration: Swallow capsules whole with water—do not chew, crush, or break 2
• Dietary restriction: Avoid grapefruit juice throughout treatment (increases budesonide blood levels) 2

Treatment Algorithm

Patient Selection Criteria

Start targeted-release budesonide when ALL of the following are met:

• Biopsy-confirmed primary IgA nephropathy
• eGFR ≥35 mL/min/1.73 m²
• Persistent proteinuria ≥0.5 g/24h (or UPCR ≥0.8 g/g)
• Already on maximally tolerated RAS blockade for ≥90 days 3
• Blood pressure optimized to target <120/70 mm Hg 3

Expected Outcomes

The NefIgArd phase 3 trial demonstrated:

• Primary endpoint: 5.05 mL/min/1.73 m² preservation of eGFR over 2 years compared to placebo (p<0.0001) 1
• Proteinuria reduction: 24.4% decrease at 9 months, sustained through 2-year follow-up 4
• Kidney failure risk: 70% relative risk reduction in time to 30% eGFR decline or kidney failure 5
• Response timing: 45.9% show very early response (≥30% proteinuria reduction) by 3 months, increasing to 78.3% by 6 months 6

Evidence Strength

The recommendation is based on the 2023 NefIgArd phase 3 trial 1, the highest-quality and most recent evidence available—a multicenter, randomized, double-blind, placebo-controlled study of 364 patients across 20 countries with 2-year follow-up. This represents Level 1 evidence for mortality and morbidity outcomes in IgA nephropathy.

Notably, patients from mainland China showed numerically greater benefit (9.6 mL/min/1.73 m² eGFR preservation) compared to the global population, with excellent tolerability 5. The 16 mg dose consistently outperformed the 8 mg dose in earlier phase 2b trials 4.

Safety Monitoring

Common Side Effects (>10% incidence):

• Peripheral edema (17%)
• Hypertension (12%)
• Muscle spasms (12%)
• Acne (11%)
• Headache (10%) 1

Critical Monitoring Requirements

During 9-month treatment phase:

• Monitor serum creatinine and potassium every 2-4 weeks initially, then monthly
• Check blood pressure at each visit
• Screen for signs of hypercorticism: moon facies, buffalo hump, striae, acne 2
• Assess for infection symptoms (fever, cough, abdominal pain)—corticosteroids increase infection risk 2

Contraindications and precautions:

• Active tuberculosis or untreated latent TB (screen before starting) 2
• Active systemic infections
• Recent exposure to chickenpox or measles without immunity 2
• Severe liver impairment (budesonide undergoes hepatic metabolism)

Drug Interactions

Avoid strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, erythromycin)—these increase budesonide exposure 8-fold. If unavoidable, consider discontinuing budesonide temporarily 2.

Critical Clinical Pitfalls

1. Do NOT use conventional systemic corticosteroids instead—targeted-release budesonide delivers medication to the distal ileum where Gd-IgA1 production occurs, minimizing systemic exposure and side effects compared to oral prednisone 7, 8

2. Do NOT continue beyond 9 months—the NefIgArd trial showed durable benefit persists through 15-month follow-up after stopping treatment 1. Prolonged corticosteroid exposure increases risks of adrenal suppression, osteoporosis, and infection 2

3. Do NOT start if eGFR <35 mL/min/1.73 m²—this population was excluded from trials and may not benefit

4. Do NOT delay treatment excessively—patients closer to diagnosis (mean 29 months vs 65 months) show better early response rates 6. Active histologic lesions (M1, E1, S1, T1) on biopsy predict better proteinuria reduction 6

5. Do NOT stop RAS blockade—continue maximally tolerated ACEi/ARB throughout and after budesonide treatment 3, 1

Post-Treatment Management

After completing 9 months of budesonide:

• Discontinue abruptly (no taper required for this formulation)
• Continue supportive care: RAS blockade, blood pressure control <120/70 mm Hg, dietary sodium <2 g/day 3
• Add SGLT2 inhibitor if not already prescribed—emerging evidence supports benefit in IgAN 9, 10
• Monitor proteinuria and eGFR every 3 months for first year, then every 6 months
• Consider alternative immunosuppression if proteinuria remains >1 g/day at 6 months or eGFR continues declining 10

The treatment effect is disease-modifying, not merely symptomatic—benefits persist well beyond the 9-month treatment period, distinguishing this from conventional immunosuppression 1, 8.